Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

CURE vs. LABU: which is better?

Bottom line

CURE vs LABU: the short answer

CURE (Direxion Daily Healthcare Bull 3X ETF) and LABU (Direxion Daily S&P Biotech Bull 3X ETF) are both etfs.

But LABU is far broader, holding 163 positions to 67 for CURE, so beyond the top names it adds exposure CURE doesn't have.

CURE is cheaper at 0.94% vs 0.96% — a difference of $2.00 a year per $10,000 invested.

Over five years, CURE returned +8.6% a year vs −39.6% for LABU.

Updated Nov 19, 2026

CURE vs LABU side by side

CURELABU
TypeETFETF
Fund familyDirexionDirexion
CategoryLeveraged & InverseLeveraged & Inverse
Expense ratio0.94%0.96%
Annual cost per $10k$94$96
10-yr cost on $10k (prospectus)$1,155$1,178
Max front loadNoneNone
12b-1 fee0%0%
1-yr return+22.9%+78.7%
5-yr return (annualized)+8.6%−39.6%
10-yr return (annualized)+13.6%−20.8%
Best quarter+46.9%+161.5%
Worst quarter−45.8%−67.4%
Net assets (fund)$171.7M$494.4M
Number of holdings67163
Portfolio turnover1%107%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearCURELABUDifference
2025+22.9%+78.7%−55.9%
2024−8.5%−25.9%+17.4%
2023−9.8%−13.4%+3.7%
2022−20.4%−80.3%+59.9%
2021+87.4%−64.3%+151.7%
2020+5.1%+74.7%−69.6%
2019+55.9%+74.6%−18.8%
2018+2.9%−57.3%+60.2%
2017+69.3%+148.7%−79.4%
2016−17.4%−63.0%+45.6%

Source: Fund prospectus bar charts

Holdings overlap

6 of CURE's top 25 holdings also appear in LABU's top 25.

Shared top holdings
HoldingCURELABU
Dreyfus18.79%15.86%
N/a8.28%3.87%
Goldman Sachs Liq Es Fd A8.19%5.35%
Goldman Financial7.51%14.83%
N/a3.34%3.87%
N/a1.12%3.87%

Source: SEC Form N-PORT

CURE top 10

  1. Dreyfus — 18.79%
  2. Eli Lilly & Company — 10.41%
  3. N/a — 8.28%
  4. Goldman Sachs Liq Es Fd A — 8.19%
  5. Goldman Financial — 7.51%
  6. Johnson & Johnson — 7.07%
  7. Abbvie Inc — 5.08%
  8. Unitedhealth Group Inc — 4.31%
  9. Merck & Company Inc — 3.68%
  10. N/a — 3.34%

LABU top 10

  1. Dreyfus — 15.86%
  2. Goldman Financial — 14.83%
  3. N/a — 9.63%
  4. N/a — 7.30%
  5. Goldman Sachs Liq Es Fd A — 5.35%
  6. N/a — 4.85%
  7. N/a — 3.87%
  8. Apogee Therapeutics Inc — 1.11%
  9. Oruka Therapeutics Inc — 1.03%
  10. Dianthus Therapeutics Inc — 0.96%

FAQ

What is the difference between CURE and LABU?
CURE (Direxion Daily Healthcare Bull 3X ETF) and LABU (Direxion Daily S&P Biotech Bull 3X ETF) are both etfs. But LABU is far broader, holding 163 positions to 67 for CURE, so beyond the top names it adds exposure CURE doesn't have.
Which is cheaper, CURE or LABU?
CURE has the lower expense ratio (0.94%).
Should I own both CURE and LABU?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.